139 related articles for article (PubMed ID: 25534718)
1. Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers.
Baretta Z; Olopade OI; Huo D
Breast; 2015 Apr; 24(2):131-6. PubMed ID: 25534718
[TBL] [Abstract][Full Text] [Related]
2. Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?
Sighoko D; Liu J; Hou N; Gustafson P; Huo D
Oncologist; 2014 Jun; 19(6):592-601. PubMed ID: 24807915
[TBL] [Abstract][Full Text] [Related]
3. Synchronous and metachronous bilateral breast cancer: a long-term single-institution experience.
Díaz R; Munárriz B; Santaballa A; Palomar L; Montalar J
Med Oncol; 2012 Mar; 29(1):16-24. PubMed ID: 21193967
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
5. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
6. Bilateral Breast Cancer After Multimodality Treatment: A Report of Clinical Outcomes in an Asian Population.
Wadasadawala T; Lewis S; Parmar V; Budrukkar A; Gupta S; Nair N; Shet T; Badwe R; Sarin R
Clin Breast Cancer; 2018 Aug; 18(4):e727-e737. PubMed ID: 29254601
[TBL] [Abstract][Full Text] [Related]
7. Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer.
Ding S; Sun X; Lu S; Wang Z; Chen X; Shen K
Breast; 2021 Jun; 57():71-79. PubMed ID: 33774461
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer.
Sandberg ME; Hartman M; Klevebring D; Eloranta S; Ploner A; Hall P; Czene K
Breast Cancer Res Treat; 2012 Jul; 134(2):793-800. PubMed ID: 22622811
[TBL] [Abstract][Full Text] [Related]
9. Clinical Features and Survival of Single Hormone Receptor-Positive Breast Cancer: A Population-Based Study of 531,605 Patients.
Lv M; Mao Y; Song Y; Wang Y; Liu X; Wang X; Nie G; Wang H
Clin Breast Cancer; 2020 Oct; 20(5):e589-e599. PubMed ID: 32565109
[TBL] [Abstract][Full Text] [Related]
10. The prognosis of synchronous and metachronous bilateral breast cancer in Chinese patients.
Liang X; Li D; Geng W; Cao X; Xiao C
Tumour Biol; 2013 Apr; 34(2):995-1004. PubMed ID: 23296702
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
[TBL] [Abstract][Full Text] [Related]
12. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
[TBL] [Abstract][Full Text] [Related]
13. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
Karsten M; Stempel M; Radosa J; Patil S; King TA
Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
[TBL] [Abstract][Full Text] [Related]
14. Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.
Mezencev R; Švajdler M
Breast Cancer; 2017 May; 24(3):400-410. PubMed ID: 27502779
[TBL] [Abstract][Full Text] [Related]
15. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
16. Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
Zheng YZ; Wang L; Hu X; Shao ZM
Oncotarget; 2015 Sep; 6(26):22985-95. PubMed ID: 26036636
[TBL] [Abstract][Full Text] [Related]
17. Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.
Senkus E; Szade J; Pieczyńska B; Zaczek A; Pikiel J; Sosińska-Mielcarek K; Karpińska A; Jassem J
Int J Clin Exp Pathol; 2014; 7(1):353-63. PubMed ID: 24427357
[TBL] [Abstract][Full Text] [Related]
18. Receptor changes in metachronous breast tumors--our experience of 10 years.
Bhullar JS; Unawane A; Subhas G; Poonawala H; Dubay L; Ferguson L; Goriel Y; Jacobs MJ; Kolachalam RB; Silapaswan S; Mittal VK
Am J Surg; 2012 Mar; 203(3):405-9; discussion 409. PubMed ID: 22206855
[TBL] [Abstract][Full Text] [Related]
19. Meningioma and breast cancer: survival of patients with synchronous and metachronous meningioma and breast cancer.
Lavrador JP; Pinto MV; Lemos LM; Ribeiro C; Santos AP
J Neurooncol; 2018 Jan; 136(1):163-171. PubMed ID: 29119423
[TBL] [Abstract][Full Text] [Related]
20. Risk of second breast cancers after lobular carcinoma in situ according to hormone receptor status.
Mao K; Yang Y; Wu W; Liang S; Deng H; Liu J
PLoS One; 2017; 12(5):e0176417. PubMed ID: 28467490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
